<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MD</journal-id>
<journal-title>Marine Drugs</journal-title>
<abbrev-journal-title>MD</abbrev-journal-title>
<issn pub-type="epub">1660-3397</issn>
<publisher>
<publisher-name>Molecular Diversity Preservation International</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3390/md9102075</article-id>
<article-id pub-id-type="publisher-id">marinedrugs-09-02075</article-id>
<article-categories>
<subj-group>
<subject>Article</subject></subj-group></article-categories>
<title-group>
<article-title>Vasorelaxation, Induced by <italic>Dictyota pulchella</italic> (Dictyotaceae), a Brown Alga, Is Mediated via Inhibition of Calcium Influx in Rats</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Queiroz</surname><given-names>Thyago M.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Machado</surname><given-names>Natália T.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Furtado</surname><given-names>Fabíola F.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Oliveira-Filho</surname><given-names>Abrahão A.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Alustau</surname><given-names>Maria C.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Figueiredo</surname><given-names>Camila S.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Miranda</surname><given-names>George E. C.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Barbosa-Filho</surname><given-names>José M.</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Braga</surname><given-names>Valdir A.</given-names></name><xref ref-type="corresp" rid="c1-marinedrugs-09-02075">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>Medeiros</surname><given-names>Isac A.</given-names></name></contrib>
<aff id="af1-marinedrugs-09-02075">Biotechnology Center, Federal University of Paraiba, João Pessoa, PB 58.051-900, Brazil; E-Mails: <email>thyagoqueiroz@gmail.com</email> (T.M.Q.); <email>naty_tabosa@msn.com</email> (N.T.M.); <email>fabiola.fialho@gmail.com</email> (F.F.F.); <email>abrahao.farm@gmail.com</email> (A.A.O.-F); <email>karminha@gmail.com</email> (M.C.A); <email>mila_farma@hotmail.com</email> (C.S.F.); <email>mirandag@dse.ufpb.br</email> (G.E.C.M.); <email>jbarbosa@ltf.ufpb.br</email> (J.M.B.-F.); <email>isac@ltf.ufpb.br</email> (I.A.M.)</aff></contrib-group>
<author-notes>
<corresp id="c1-marinedrugs-09-02075">
<label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>valdir@ltf.ufpb.br</email>; Tel.: +55-083-3216-7366; Fax: +55-083-3362-2259.</corresp></author-notes>
<pub-date pub-type="collection">
<year>2011</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>10</month>
<year>2011</year></pub-date>
<volume>9</volume>
<issue>10</issue>
<fpage>2075</fpage>
<lpage>2088</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>8</month>
<year>2011</year></date>
<date date-type="rev-recd">
<day>13</day>
<month>10</month>
<year>2011</year></date>
<date date-type="accepted">
<day>17</day>
<month>10</month>
<year>2011</year></date></history>
<permissions>
<copyright-statement>© 2011 by the authors; licensee MDPI, Basel, Switzerland</copyright-statement>
<copyright-year>2011</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p></license></permissions>
<abstract>
<p>This study aimed to investigate the cardiovascular effects elicited by <italic>Dictyota pulchella</italic>, a brown alga, using <italic>in vivo</italic> and <italic>in vitro</italic> approaches. In normotensive conscious rats, CH<sub>2</sub>Cl<sub>2</sub>/MeOH Extract (CME, 5, 10, 20 and 40 mg/kg) from <italic>Dictyota pulchella</italic> produced dose-dependent hypotension (−4 ± 1; −8 ± 2; −53 ± 8 and −63 ± 3 mmHg) and bradycardia (−8 ± 6; −17 ± 11; −257 ± 36 and −285 ± 27 b.p.m.). In addition, CME and Hexane/EtOAc Phase (HEP) (0.01–300 μg/mL) from <italic>Dictyota pulchella</italic> induced a concentration-dependent relaxation in phenylephrine (Phe, 1 μM)-pre-contracted mesenteric artery rings. The vasorelaxant effect was not modified by the removal of the vascular endothelium or pre-incubation with KCl (20 mM), tetraethylammonium (TEA, 3 mM) or tromboxane A<sub>2</sub> agonist U-46619 (100 nM). Furthermore, CME and HEP reversed CaCl<sub>2</sub>-induced vascular contractions. These results suggest that both CME and HEP act on the voltage-operated calcium channel in order to produce vasorelaxation. In addition, CME induced vasodilatation after the vessels have been pre-contracted with L-type Ca<sup>2+</sup> channel agonist (Bay K 8644, 200 nM). Taken together, our data show that CME induces hypotension and bradycardia <italic>in vivo</italic> and that both CME and HEP induce endothelium-independent vasodilatation <italic>in vitro</italic> that seems to involve the inhibition of the Ca<sup>2+</sup> influx through blockade of voltage-operated calcium channels.</p></abstract>
<kwd-group>
<kwd>calcium</kwd>
<kwd>hypotension</kwd>
<kwd>mesenteric artery</kwd>
<kwd>vasodilatation</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>1. Introduction</title>
<p>Marine algae are recognized as rich sources of structurally-diverse-biologically-active compounds with great pharmaceutical and biomedical potentials. Researchers worldwide have demonstrated that marine algae derived compounds exhibit various biological activities such as anticoagulant [<xref ref-type="bibr" rid="b1-marinedrugs-09-02075">1</xref>,<xref ref-type="bibr" rid="b2-marinedrugs-09-02075">2</xref>], anti-viral [<xref ref-type="bibr" rid="b3-marinedrugs-09-02075">3</xref>,<xref ref-type="bibr" rid="b4-marinedrugs-09-02075">4</xref>], antioxidant [<xref ref-type="bibr" rid="b5-marinedrugs-09-02075">5</xref>,<xref ref-type="bibr" rid="b6-marinedrugs-09-02075">6</xref>], anti-allergic [<xref ref-type="bibr" rid="b7-marinedrugs-09-02075">7</xref>], anti-cancer [<xref ref-type="bibr" rid="b8-marinedrugs-09-02075">8</xref>,<xref ref-type="bibr" rid="b9-marinedrugs-09-02075">9</xref>] and as adjuvants for treating cardiopathies [<xref ref-type="bibr" rid="b10-marinedrugs-09-02075">10</xref>]. Despite the ascending number of new findings regarding marine algae metabolites possessing biological activity in the last three decades, few products showing real pharmaceutical potential have been identified or developed [<xref ref-type="bibr" rid="b11-marinedrugs-09-02075">11</xref>,<xref ref-type="bibr" rid="b12-marinedrugs-09-02075">12</xref>].</p>
<p>Marine brown algae have innumerous families, with the Dictyotaceae family being the best studied among them. The genus Dictyota is represented by more than 40 species, thus being the richest genus of the Dictyotaceae family. It is also one of the most abundant seaweeds in tropical marine habitats. The Dictyotaceae family produces a significant number of secondary metabolites, especially diterpenes [<xref ref-type="bibr" rid="b13-marinedrugs-09-02075">13</xref>]. Terpenoids constitute the largest family of natural products [<xref ref-type="bibr" rid="b14-marinedrugs-09-02075">14</xref>,<xref ref-type="bibr" rid="b15-marinedrugs-09-02075">15</xref>] and are classified by the homologous series of number of five carbon isoprene units in their structure: hemiterpenes C<sub>5</sub> (1 isoprene unit), monoterpenes C<sub>10</sub> (2 isoprene units), sesquiterpenes C<sub>15</sub> (3 isoprene units), diterpenes C<sub>20</sub> (4 isoprene units), triterpenes C<sub>30</sub> (6 isoprene units) [<xref ref-type="bibr" rid="b16-marinedrugs-09-02075">16</xref>].</p>
<p>Many reports have extensively shown that several classes of diterpenoids exert significant cardiovascular effects [<xref ref-type="bibr" rid="b17-marinedrugs-09-02075">17</xref>–<xref ref-type="bibr" rid="b19-marinedrugs-09-02075">19</xref>]. It has also been reported that some classes of diterpenes showed significant systemic hypotensive and coronary vasodilatory effects accompanied by gradual decrease in heart rate [<xref ref-type="bibr" rid="b20-marinedrugs-09-02075">20</xref>,<xref ref-type="bibr" rid="b21-marinedrugs-09-02075">21</xref>]. The studies pointed at diterpenoids as promising sources for new prototypes in the discovery and development of novel cardiovascular therapeutic agents [<xref ref-type="bibr" rid="b19-marinedrugs-09-02075">19</xref>].</p>
<p>Cardiovascular diseases are the leading death cause in developed and developing countries [<xref ref-type="bibr" rid="b22-marinedrugs-09-02075">22</xref>], causing a great impact not only on human health, but also in social and economic areas. In an attempt to reduce this impact, several research groups in recent decades have worked extensively to improve the treatment of cardiovascular diseases including the discovery of new therapy strategies and drugs [<xref ref-type="bibr" rid="b23-marinedrugs-09-02075">23</xref>,<xref ref-type="bibr" rid="b24-marinedrugs-09-02075">24</xref>].</p>
<p>Considering that marine algae constitute great sources of bioactive compounds, the aim of this study was to investigate the mechanisms underlying the cardiovascular effects induced by the brown algae <italic>Dictyota pulchella</italic> in rats. To reach that goal, we employed <italic>in vivo</italic> and <italic>in vitro</italic> approaches.</p></sec>
<sec sec-type="results|discussion">
<title>2. Results and Discussion</title>
<sec>
<title>2.1. <italic>Dictyota pulchella</italic> Elicits Hypotension and Bradycardia in Rats</title>
<p>Mean arterial pressure (MAP) and heart rate (HR) were recorded before (baseline) and after intravenous administration of CH<sub>2</sub>Cl<sub>2</sub>/MeOH extract from <italic>Dictyota pulchella</italic> (CME, 5, 10, 20 and 40 mg/kg body weight, randomly) in conscious normotensive rats. CME elicited a dose-dependent hypotension (−4 ± 1; −8 ± 2; −53 ± 8 and −63 ± 3 mmHg) and bradycardia (−8 ± 6; −17 ± 11; −257 ± 36 and −285 ± 27 b.p.m.) as illustrated in <xref ref-type="fig" rid="f1-marinedrugs-09-02075">Figure 1A,B</xref>.</p>
<p>It is well-known that anesthesia modifies the levels of blood pressure and heart rate interfering with central regulatory mechanisms involved in BP regulation, such as the baroreflex, by producing depression of the central nervous system synapses, altering the autonomic responses [<xref ref-type="bibr" rid="b25-marinedrugs-09-02075">25</xref>]. In order to avoid the possible influence of anesthesia and surgical stress on cardiovascular parameters [<xref ref-type="bibr" rid="b26-marinedrugs-09-02075">26</xref>], our studies were carried out in conscious freely moving rats.</p>
<p>In the present study, the acute administration of CME induced marked hypotension and bradycardia in conscious rats (<xref ref-type="fig" rid="f1-marinedrugs-09-02075">Figure 1B</xref>). It is important to note that reduction in blood pressure due to vasodilation is usually followed by reflex tachycardia. However, under our experimental conditions, in addition to hypotension, CME induced bradycardia, which could be explained, at least in part, by a possible direct effect of the CME on the heart. Although this is an interesting possibility, this hypothesis awaits further investigation.</p>
<p>Although we demonstrated that CME can produce hypotension in normotensive rats, the beneficial effects of this marine algae on experimental hypertension and its clinical relevance still awaits further investigation.</p></sec>
<sec>
<title>2.2. <italic>Dictyota pulchella</italic> Elicits Vasorelaxation Mediated by the Blockade of Calcium Influx in Isolated Mesenteric Artery Rings</title>
<p>Based on the reports highlighting that the vascular smooth muscle tone plays an important role in maintaining blood pressure [<xref ref-type="bibr" rid="b27-marinedrugs-09-02075">27</xref>], we investigated the possible vasorelaxant effect elicited by <italic>Dictyota pulchella</italic> in isolated superior mesenteric arteries. An important layer in the regulation of vascular tone is the endothelium. For many years, this layer was considered to be an inert barrier that separated flowing blood from underlying tissue. Over time, it has been established that the endothelium plays an active role in regulating hemostasis, cellular and nutrient trafficking, and vasomotor tone [<xref ref-type="bibr" rid="b28-marinedrugs-09-02075">28</xref>]. Endothelial cells are able to produce both vasoconstrictive and vasodilating substances. The main endothelium-derived relaxing factors (EDRF) are nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). Among the contracting factors are endothelin-1, thromboxane A<sub>2</sub> and reactive oxygen species [<xref ref-type="bibr" rid="b29-marinedrugs-09-02075">29</xref>]. To evaluate the possible role played by the endothelium in the hypotension elicited by <italic>Dictyota pulchella</italic> observed <italic>in vivo</italic>, mesenteric artery rings were pre-contracted with phenylephrine (1 μM), a α<sub>1</sub>-adrenoceptors agonist. In the presence of this contracting agent, CME (0.01–500 μg/mL) induced a concentration-dependent relaxation (Maximum Response = 101.4 ± 4.5%; EC<sub>50</sub> = 22.35 ± 5.09 μg/mL, <italic>n</italic> = 6) and this effect was not modified by vascular endothelium removal (Maximum Response = 103.3 ± 8.3%; EC<sub>50</sub> = 21.43 ± 8.98 μg/mL, <italic>n</italic> = 6) (<xref ref-type="fig" rid="f2-marinedrugs-09-02075">Figure 2A</xref>). Similar results were found in the presence of Hexane/EtOAc phase from <italic>Dictyota pulchella</italic> (HEP) (0.01–500 μg/mL), which induced a concentration-dependent vasodilatation in both intact (Maximum Response = 80.6 ± 5.8%; EC<sub>50</sub> = 24.1 ± 8.95 μg/mL, <italic>n</italic> = 6) or denuded-endothelium (Maximum Response = 95.6 ± 7.5%; EC<sub>50</sub> = 23.7 ± 5.65 μg/mL, <italic>n</italic> = 6) (<xref ref-type="fig" rid="f2-marinedrugs-09-02075">Figure 2B</xref>).</p>
<p>Potassium channels (K<sup>+</sup> channels) appear to play a crucial role in controlling the cellular membrane potential and in the vascular tone. Potassium channel openers exert their biological effects by increasing the probability of opening K<sup>+</sup> channels and a number of substances that act on K<sup>+</sup> channels have been shown to dilate arteries by causing hyperpolarization in vascular smooth muscle cells [<xref ref-type="bibr" rid="b30-marinedrugs-09-02075">30</xref>]. In addition several natural products have been shown to induce vasorelaxant effects through the activation of K<sup>+</sup> channels [<xref ref-type="bibr" rid="b31-marinedrugs-09-02075">31</xref>–<xref ref-type="bibr" rid="b33-marinedrugs-09-02075">33</xref>]. Aiming to investigate involvement of potassium channels (K<sup>+</sup>) in the vasorelaxant activity elicited by CME, the preparations were pre-incubated with Tyrode’s modified solution containing KCl (20 mM) or with tetraethylammonium (TEA, 3 mM), a non-selective K<sup>+</sup> channel blocker. In both preparations, the vasorelaxant activity was not changed (Maximum Response = 102.3 ± 4.8%; EC<sub>50</sub> = 25.40 ± 6.05 μg/mL; and Maximum Response = 111.2 ± 5.3%; CE<sub>50</sub> = 16.70 ± 3.61 μg/mL; <italic>n</italic> = 7, respectively) as shown in <xref ref-type="fig" rid="f3-marinedrugs-09-02075">Figure 3A</xref>. These responses were no different from the control curve, suggesting that K<sup>+</sup> channels are not involved in the vasorelaxant effect elicited by CME.</p>
<p>To test the hypothesis that CME produces vasorelaxant effects independent of the vasoconstrictor agent used in the preparation, mesenteric artery rings were incubated with tromboxane A<sub>2</sub> agonist U-46619 (100 nM). In the presence of U-46619, CME induced concentration-dependent vasodilatation (Maximum Response = 90.3 ± 7.8%; EC<sub>50</sub> = 24.63 ± 4.04 μg/mL, <italic>n</italic> = 6) similar to the response found by Phe-contracted mesenteric artery rings (<xref ref-type="fig" rid="f3-marinedrugs-09-02075">Figure 3B</xref>).</p>
<p>In addition, CME produced relaxation in isolated arteries pre-contracted with KCl (60 mM). KCl depolarization elicits contraction by allowing the extracellular Ca<sup>2+</sup> influx through voltage-dependent (L- and T-type) Ca<sup>2+</sup> channels and subsequent calcium release from the sarcoplasmic reticulum. Due to the fact that the membrane potential is essentially clamped by the high K<sup>+</sup> solution, the mechanism by which relaxation can be produced is through blockade of voltage-dependent Ca<sup>2+</sup> channels, but not by other mediators that cause hyperpolarization [<xref ref-type="bibr" rid="b34-marinedrugs-09-02075">34</xref>]. After exposure to high concentrations of extracellular K<sup>+</sup> (KCl, 60 mM), CME induced concentration-dependent vasodilatation (Maximum Response = 97.7 ± 4.0%; EC<sub>50</sub> = 34.57 ± 5.11 mg/mL; <italic>n</italic> = 6). Under the same experimental condition, HEP induced concentration-dependent vasodilatation (Maximum Response = 113.5 ± 6.1%; EC<sub>50</sub> = 10.92 ± 2.81 μg/mL; <italic>n</italic> = 6) (<xref ref-type="fig" rid="f3-marinedrugs-09-02075">Figure 3C</xref>). Furthermore, both CME and HEP relaxed arterial segments pre-contracted with KCl (60 mM) suggesting that CME and HEP block Ca<sup>2+</sup> entry through voltage-dependent Ca<sup>2+</sup> channels (Ca<sub>v</sub>).</p>
<p>In order to further investigate the hypothesis that CME and HEP act through the blockade of calcium influx, CME and HEP were tested in the presence of CaCl<sub>2</sub>-induced contractions in a depolarizing medium without calcium. This protocol was based on the fact that CaCl<sub>2</sub>-induced contractions are elicited, almost exclusively, through Ca<sup>2+</sup> influx, since the depolarization promoted by high concentrations of extracellular K<sup>+</sup> induces the opening of voltage-dependent Ca<sup>2+</sup> channels [<xref ref-type="bibr" rid="b35-marinedrugs-09-02075">35</xref>]. Under this experimental condition, CME and HEP (0.03; 0.3; 10; 30 and 100 μg/mL) produced a non-parallel and concentration-dependent rightward shift of the CaCl<sub>2</sub> concentration–response curve significantly reducing the maximal response (Maximum Response = 116.1; 122.7; 84; 40.7; 7.6% and 130; 126.2; 46.8; 22.8; 7.3%, respectively) as illustrated in <xref ref-type="fig" rid="f4-marinedrugs-09-02075">Figure 4A,B</xref>.</p>
<p>Voltage-dependent calcium channels (Ca<sub>v</sub>) are transmembrane proteins that provide influx of calcium for a variety of intracellular activities in excitable cells. In blood vessels, this calcium entry produces vasoconstriction and blockers of Ca<sub>v</sub> have been used to treat cardiovascular disorders. Voltage-dependent calcium channels consist of different subunits: the α<sub>1</sub>-subunit, which contains four homologous transmembrane domains encompassing the pore, the voltage sensor and the selectivity filter; and the β, α2δ and γ auxiliary subunits. The α<sub>1</sub>-subunits have been classified as Ca<sub>v</sub>1.1, Ca<sub>v</sub>1.2, Ca<sub>v</sub>1.3, Ca<sub>v</sub>1.4 (L-type Ca<sub>v</sub>), Ca<sub>v</sub>2.1 (P/Q-type Ca<sub>v</sub>), Ca<sub>v</sub>2.2 (N-type Ca<sub>v</sub>), Ca<sub>v</sub>2.3 (R-type Ca<sub>v</sub>), Ca<sub>v</sub>3.1, Ca<sub>v</sub>3.2 and Ca<sub>v</sub>3.3 (T-type Ca<sub>v</sub>). In the vascular smooth muscle cells two types are expressed: L-type and T-type. The first ones are more expressed in these cells and exert an important role in the regulation of the vascular tone [<xref ref-type="bibr" rid="b36-marinedrugs-09-02075">36</xref>,<xref ref-type="bibr" rid="b37-marinedrugs-09-02075">37</xref>].</p>
<p>In order to examine which subtype of Ca<sub>v</sub> was involved in the vasorelaxant effect elicited by CME, a contraction with Bay K 8644 (200 nM), a L-type Ca<sup>2+</sup> channel agonist, was evoked. CME induced concentration-dependent vasodilatation (Maximum Response = 113.3 ± 6.7%; EC<sub>50</sub> = 19.45 ± 6.66 μg/mL, <italic>n</italic> = 7) and it was similar to the response found under Phe-induced contractions (<xref ref-type="fig" rid="f5-marinedrugs-09-02075">Figure 5</xref>). These data indicate that L-type Ca<sub>v</sub> channels could be involved in the vasorelaxant effect induced by CME.</p>
<p>In order to investigate a role for dihydropyridine calcium channels, rings were incubated with nifedipine. In the presence of nifedipine, CME (0.01–500 μg/mL) induced a concentration-dependent relaxation (Maximum Response = 63.6 ± 2.9%; EC<sub>50</sub> = 25.4 ± 11.0 μg/mL, <italic>n</italic> = 6). The maximum response was different to the response found by Phe-contracted mesenteric artery rings (<xref ref-type="fig" rid="f6-marinedrugs-09-02075">Figure 6A</xref>). In addition, in the presence of nifedipine, HEP (0.01–500 μg/mL) induced a concentration-dependent relaxation (Maximum Response = 69.8 ± 1.7%; EC<sub>50</sub> = 24.4 ± 10.3 μg/mL, <italic>n</italic> = 6). The maximum response was different to the response found by Phe-contracted mesenteric artery rings (<xref ref-type="fig" rid="f6-marinedrugs-09-02075">Figure 6B</xref>). Based on these findings, it can be suggested that the endothelium-independent vasodilatation induced by both CME and HEP involves, at least in part, the inhibition of the Ca<sup>2+</sup> influx through blockade of calcium channels.</p></sec></sec>
<sec>
<title>3. Experimental Section</title>
<sec>
<title>3.1. Algal Material and Preparation of CH<sub>2</sub>Cl<sub>2</sub>/MeOH Extract (CME) and Hexane/EtOAc Phase (HEP) from <italic>Dictyota pulchella</italic></title>
<p>The brown alga <italic>Dictyota pulchella</italic> Hörnig and Schnetter (Dictyotaceae, Phaeophyceae) was collected at Bessa Beach, João Pessoa, State of Paraíba, Brazil, at coordinates 07°04′01″S and 34°49′35″W in February 2009 at a depth of 1 m and it was identified by George Emmanuel C. de Miranda. A voucher specimen (JPB 41771) is deposited at Lauro Pires Xavier Herbarium of the Federal University of Paraíba.</p>
<p>The freeze-dried material (240 g) was extracted with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (2:1) at room temperature. The concentrated extract (10 g) was partitioned by vacuum filtration with silica gel that uses the solvents Hexano/EtOAc (9:1) to give the fraction Hexano/EtOAc (9:1) (850 mg).</p>
<p>The CH<sub>2</sub>Cl<sub>2</sub>/MeOH extract (CME) and Hexane/EtOAc phase (HEP) were prepared in a mixture of distilled water (<italic>in vitro</italic> experiments) or NaCl 0.9 % solution (<italic>in vivo</italic> experiments) and cremophor (0.013% v/v) and kept at −4° C. The stock solution was diluted to the desired concentrations with distilled water or isotonic saline just before use. The final concentration of cremophor in the bath had no effect when tested in control preparations (data not shown).</p></sec>
<sec>
<title>3.2. Drugs and Solutions</title>
<p>The following drugs were used: Cremophor EL, <sc>l</sc>-phenylephrine chloride (Phe), acetylcholine chloride (Ach), tetraethylammonium (TEA), S(−)-Bay K 8644, sodium nitroprusside, Ethylene glycol-bis(2-aminoethylether)-<italic>N</italic>,<italic>N</italic>,<italic>N′</italic>,<italic>N′</italic>-tetraacetic acid (EGTA) and 9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F<sub>2α</sub> (U 46619), were purchased from Sigma Chemical (Sigma Chemical Co., St. Louis, MO, USA). Heparin sodium salt (Roche Brazil, São Paulo, Brazil), sodium thiopental (Cristália, São Paulo, SP, Brazil). The substances were dissolved in distilled water (<italic>in vitro</italic> experiments) or in NaCl 0.9% solution (<italic>in vivo</italic> experiments).</p>
<p>The composition of the Tyrode’s solution used to bath isolated rings was (mM): NaCl, 158.3; KCl, 4.0; CaCl<sub>2</sub>, 2.0; MgCl<sub>2</sub>, 1.05; NaH<sub>2</sub>PO<sub>4</sub>, 0.42; NaHCO<sub>3</sub>, 10.0 and glucose, 5.6.</p></sec>
<sec>
<title>3.3. Animals</title>
<p>Male Wistar rats (250–300 g) were used in all experiments. They were housed in conditions of controlled temperature (21 ± 1 °C) and exposed to a 12 h light-dark cycle with free access to food (Labina<sup>®</sup>, PURINA, Brazil) and tap water. All procedures described in the present study are in agreement with Institutional Animal Care and Use Committee of the Federal University of Paraiba (CEPA/LTF protocol No. 0208/10).</p></sec>
<sec>
<title>3.4. <italic>In Vivo</italic> Experiments</title>
<p>Intra-aortic blood pressure was recorded using a technique described by Braga [<xref ref-type="bibr" rid="b37-marinedrugs-09-02075">37</xref>] under sodium thiopental anesthesia (45 mg/kg, i.v.), the lower abdominal aorta and inferior vena cava were cannulated via left femoral artery and vein using polyethylene catheters. Thereafter, catheters were filled with heparinized saline solution and tunneled under the skin to emerge between the scapulae. Arterial pressure was measured 24 h after surgery by connecting the arterial catheter to a pre-calibrated pressure transducer (MLT0380/D, ADInstruments, Australia) and connected to a computer (Mikro-tip Blood pressure system, ADInstruments, Australia) running the LabChart software (ADInstruments, Australia). The data were sampled at 2000 Hz. For each pulse pressure, the computer calculated mean arterial pressure (MAP) and heart rate (HR). The venous catheter was used for drug administration.</p></sec>
<sec>
<title>3.5. <italic>In Vitro</italic> Experiments</title>
<sec>
<title>3.5.1. Tissue Preparation</title>
<p>Rats were euthanized by stunning and bleeding. The superior mesenteric artery was removed and cleaned from connective tissue and fat. Rings (1–2 mm) were obtained and placed in physiological Tyrode’s solution, maintained at 37 °C, gassed with carbogenic mixture (95% O<sub>2</sub> and 5% CO<sub>2</sub>), and maintained at pH 7.4. All preparations were stabilized under a resting tension of 0.75 g for 1 h. The solution was replaced every 15 min to prevent the accumulation of metabolites. The force of contraction was isometrically recorded by a force transducer (MLT020, ADInstruments, Australia) connected to a data acquisition system (ML870/P with LabChart version 7.0, ADInstruments, Australia). Endothelium was removed by gently rubbing the intimal surface of the vessels.</p>
<p>The presence of functional endothelium was assessed by the ability of acetylcholine (ACh) (10 μM) to induce more than 90% relaxation of pre-contracted vessels with phenylephrine (10 μM). When the relaxation to ACh was less than 10%, this was taken as evidence that the vessel segments were functionally denuded of endothelium.</p></sec>
<sec>
<title>3.5.2. Measurement of Vascular Relaxation Elicited by CME or HEP</title>
<p>The ability of extract or phase to cause vascular relaxation was evaluated in both endothelium-intact and endothelium-denuded mesenteric artery rings previously contracted by Phe (1 μM). Under the sustained contraction elicited by Phe the vessels were exposed to cumulative concentrations of CME or HEP (3, 5, 10, 30 and 50 μg/mL).</p></sec>
<sec>
<title>3.5.3. Effect of CME or HEP on KCl (60 mM) or U-46619 (100 nM)-Induced Contractions in Rings without Endothelium or after KCl (20 mM) and Tetraethylamonium (3 mM) Incubation</title>
<p>Contractions of the vessels were induced with KCl (60 mM) or U-46619 (100 nM) in rings without the endothelium. During the tonic phase of the contraction, CME or HEP (0.01–500 μg/mL) was added to the organ bath. The extent of relaxation was expressed as the percentage of KCl- or U46619-induced contraction. Furthermore, curves for CME were obtained after incubation with KCl (20 mM) or TEA (3 mM), a non-selective K<sup>+</sup> channel blocker in rings without the endothelium.</p></sec>
<sec>
<title>3.5.4. Depolarization Induced by High Extracellular K<sup>+</sup> Concentration</title>
<p>In order to access the effects of CME or HEP on voltage-gated Ca<sup>2+</sup> channels, superior mesenteric artery rings were bathed for 15 min in Ca<sup>2+</sup>-free Tyrode’s solution, prepared by omitting only CaCl<sub>2</sub> and then exposed for an additional 15 min to a high K<sup>+</sup> (60 mM) Ca<sup>2+</sup>-free solution. Under this new experimental condition, cumulative concentration-response curves to CaCl<sub>2</sub> (ranging from 1 μM to 3 mM) were obtained. CME and HEP (0.01–500 μg/mL) were added to the preparations for 30 min, and then a new cumulative concentration–response curve for CaCl<sub>2</sub> was determined. The maximal contraction obtained with the control concentration–response curve to CaCl<sub>2</sub> was taken as 100% and all values were calculated as a percentage of the maximal response. Each preparation was exposed to only one CME or HEP-concentration. All experiments were done using endothelium-denuded superior mesenteric artery rings.</p></sec>
<sec>
<title>3.5.5. Effect of CME on the Contraction Elicited by S(−)-Bay K 8644 (200 nM) or Nifedipine (1 μM) in Mesenteric Artery Rings without Endothelium</title>
<p>Contractions of the vessels were induced by S(−)-Bay K 8644 (200 nM), an activator of calcium channels sensitive to dihydropyridines, in rings without the endothelium. During the tonic phase of the contraction, CME (0.01–500 μg/mL) was added to the organ bath. The extent of relaxation was expressed as the percentage of S(−)-Bay K 8644 -induced contraction. In addition, in order to intestigate the involvement of calcium channels, nifedipine (1 μM) was used to pre-incubate the preparations prior to CME or HEP administration.</p></sec></sec>
<sec sec-type="methods">
<title>3.6. Statistical Analysis</title>
<p>Data are expressed as the mean ± SEM. When appropriate, the significance of differences was determined using one-way ANOVA following Bonferroni’s post test with GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA, USA). Throughout the results, the “maximal relaxation” corresponds to the maximum response of pre-contracted tissues to the highest concentration of drug tested. <italic>P</italic> &lt; 0.05 was considered significant.</p></sec></sec>
<sec sec-type="conclusions">
<title>4. Conclusions</title>
<p>Using combined <italic>in vivo</italic> and <italic>in vitro</italic> approaches, our data suggest that <italic>Dictyota pulchella</italic> induces hypotension and bradycardia. In addition, both extract and phase from <italic>Dictyota pulchella</italic> induce endothelium-independent vasodilatation that involves the inhibition of the Ca<sup>2+</sup> influx through blockade of voltage-operated calcium channels. More studies are needed in order to evaluate the effects of this marine alga on experimental models of diseases such as hypertension and heart failure, which will help to advance the field towards clinical trials. Eventually, these data will open new perspectives in the use of these marine brown algae for developing drugs targeting the cardiovascular system.</p></sec></body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was funded by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES). We thank José Crispin for his expert care of the animals.</p></ack>
<fn-group><fn>
<p><italic>Samples Availability:</italic> Available from the authors.</p></fn></fn-group>
<ref-list>
<title>References</title>
<ref id="b1-marinedrugs-09-02075"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Matsuura</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>K</given-names></name><name><surname>Miyazawa</surname><given-names>K</given-names></name></person-group><article-title>An anticoagulant proteoglycan from the marine green alga, <italic>Codium pugniformis</italic></article-title><source>J. Appl. Phycol</source><year>2000</year><volume>12</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1023/A:1008174115350</pub-id></citation></ref>
<ref id="b2-marinedrugs-09-02075"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Athukorala</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>Y</given-names></name></person-group><article-title>Anticoagulant activity of marine green and brown algae collected from Jeju Island in Korea</article-title><source>Bioresour. Technol</source><year>2007</year><volume>98</volume><fpage>1711</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1016/j.biortech.2006.07.034</pub-id><pub-id pub-id-type="pmid">16973353</pub-id></citation></ref>
<ref id="b3-marinedrugs-09-02075"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Artan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Karadeniz</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>Anti-HIV-1 activity of phloroglucinol derivative, 6,6′-bieckol, from Ecklonia cava</article-title><source>Bioorgan. Med. Chem</source><year>2008</year><volume>16</volume><fpage>7921</fpage><lpage>7926</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2008.07.078</pub-id></citation></ref>
<ref id="b4-marinedrugs-09-02075"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huheihel</surname><given-names>M</given-names></name><name><surname>Ishanu</surname><given-names>V</given-names></name><name><surname>Tal</surname><given-names>J</given-names></name><name><surname>Arad</surname><given-names>S</given-names></name></person-group><article-title>Activity of <italic>Porphyridium</italic> sp. polysaccharide against herpes simplex viruses <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>J. Biochem. Biophys. Methods</source><year>2002</year><volume>50</volume><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/S0165-022X(01)00186-5</pub-id><pub-id pub-id-type="pmid">11741707</pub-id></citation></ref>
<ref id="b5-marinedrugs-09-02075"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Jeon</surname><given-names>YJ</given-names></name></person-group><article-title>Antioxidant activities of enzymatic extracts from brown seaweeds</article-title><source>Bioresour. Technol</source><year>2005</year><volume>96</volume><fpage>1613</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1016/j.biortech.2004.07.013</pub-id><pub-id pub-id-type="pmid">15978995</pub-id></citation></ref>
<ref id="b6-marinedrugs-09-02075"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>Antioxidant effects of phlorotannins isolated from <italic>Ishige okamurae</italic> in free radical mediated oxidative systems</article-title><source>J. Agric. Food Chem</source><year>2008</year><volume>56</volume><fpage>7001</fpage><lpage>7009</lpage><pub-id pub-id-type="doi">10.1021/jf801133h</pub-id><pub-id pub-id-type="pmid">18616277</pub-id></citation></ref>
<ref id="b7-marinedrugs-09-02075"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>Q</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>Anti-allergic effects of phlorotannins on histamine release via binding inhibition between IgE and Fc RI</article-title><source>J. Agric. Food Chem</source><year>2008</year><volume>56</volume><fpage>12073</fpage><lpage>12080</lpage><pub-id pub-id-type="doi">10.1021/jf802732n</pub-id><pub-id pub-id-type="pmid">19053379</pub-id></citation></ref>
<ref id="b8-marinedrugs-09-02075"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Yoon</surname><given-names>NY</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name></person-group><article-title>Induction of apoptosis by phloroglucinol derivative from <italic>Ecklonia cava</italic> in MCF-7 human breast cancer cells</article-title><source>Food Chem. Toxicol</source><year>2009</year><volume>47</volume><fpage>1653</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2009.04.013</pub-id><pub-id pub-id-type="pmid">19393283</pub-id></citation></ref>
<ref id="b9-marinedrugs-09-02075"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pangestuti</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>S-K</given-names></name></person-group><article-title>Neuroprotective effects of marine algae</article-title><source>Mar. Drugs</source><year>2011</year><volume>9</volume><fpage>803</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.3390/md9050803</pub-id><pub-id pub-id-type="pmid">21673890</pub-id></citation></ref>
<ref id="b10-marinedrugs-09-02075"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelecom</surname><given-names>A</given-names></name></person-group><article-title>Secondary metabolites from marine microorganisms</article-title><source>An. Acad. Bras. Cienc</source><year>2002</year><volume>74</volume><fpage>151</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1590/S0001-37652002000100012</pub-id><pub-id pub-id-type="pmid">11960184</pub-id></citation></ref>
<ref id="b11-marinedrugs-09-02075"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname><given-names>AJ</given-names></name></person-group><article-title>Medicinal and pharmaceutical uses of seaweeds natural products: a review</article-title><source>J. Appl. Physcol</source><year>2004</year><volume>16</volume><fpage>245</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1023/B:JAPH.0000047783.36600.ef</pub-id></citation></ref>
<ref id="b12-marinedrugs-09-02075"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>APA</given-names></name><name><surname>Torres</surname><given-names>MR</given-names></name><name><surname>Pessoa</surname><given-names>C</given-names></name><name><surname>Moraes</surname><given-names>MO</given-names></name><name><surname>Rocha-Filho</surname><given-names>FD</given-names></name><name><surname>Alves</surname><given-names>APNN</given-names></name><name><surname>Costa-Lotufo</surname><given-names>LV</given-names></name></person-group><article-title><italic>In vivo</italic> growth-inhibition of Sarcoma 180 tumor by alginates from brown seaweed <italic>Sargassum vulgare</italic></article-title><source>Carbohydr. Polym</source><year>2007</year><volume>69</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2006.08.018</pub-id></citation></ref>
<ref id="b13-marinedrugs-09-02075"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siamopoulou</surname><given-names>P</given-names></name><name><surname>Bimplakis</surname><given-names>A</given-names></name><name><surname>Iliopoulou</surname><given-names>D</given-names></name><name><surname>Vagias</surname><given-names>C</given-names></name><name><surname>Cos</surname><given-names>P</given-names></name><name><surname>Vanden Berghe</surname><given-names>D</given-names></name><name><surname>Roussis</surname><given-names>V</given-names></name></person-group><article-title>Diterpenes from the brown algae <italic>Dictyota dichotoma</italic> and <italic>Dictyota linearis</italic></article-title><source>Phytochemistry</source><year>2004</year><volume>65</volume><fpage>2025</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2004.06.018</pub-id><pub-id pub-id-type="pmid">15279967</pub-id></citation></ref>
<ref id="b14-marinedrugs-09-02075"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacchettini</surname><given-names>JC</given-names></name><name><surname>Poulter</surname><given-names>CD</given-names></name></person-group><article-title>Creating isoprenoid diversity</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>1788</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1126/science.277.5333.1788</pub-id><pub-id pub-id-type="pmid">9324768</pub-id></citation></ref>
<ref id="b15-marinedrugs-09-02075"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dewick</surname><given-names>PM</given-names></name></person-group><article-title>The biosynthesis of C<sub>5</sub>–C<sub>25</sub> terpenoid compounds</article-title><source>Nat. Prod. Rep</source><year>2002</year><volume>19</volume><fpage>181</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1039/b002685i</pub-id><pub-id pub-id-type="pmid">12013278</pub-id></citation></ref>
<ref id="b16-marinedrugs-09-02075"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dubey</surname><given-names>VS</given-names></name><name><surname>Bhalla</surname><given-names>R</given-names></name><name><surname>Luthra</surname><given-names>R</given-names></name></person-group><article-title>An overview of the non-mevalonate pathway for terpenoid biosynthesis in plants</article-title><source>J. Biosci</source><year>2003</year><volume>28</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1007/BF02703339</pub-id><pub-id pub-id-type="pmid">14517367</pub-id></citation></ref>
<ref id="b17-marinedrugs-09-02075"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tirapelli</surname><given-names>CR</given-names></name><name><surname>Ambrosio</surname><given-names>SR</given-names></name><name><surname>da Costa</surname><given-names>FB</given-names></name><name><surname>de Oliveira</surname><given-names>AM</given-names></name></person-group><article-title>Evidence for the mechanisms underlying the effects of pimaradienoic acid isolated from the roots of <italic>Viguiera arenaria</italic> on rat aorta</article-title><source>Pharmacology</source><year>2004</year><volume>70</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1159/000074240</pub-id><pub-id pub-id-type="pmid">14646354</pub-id></citation></ref>
<ref id="b18-marinedrugs-09-02075"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tirapelli</surname><given-names>CR</given-names></name><name><surname>dos Anjos</surname><given-names>MNF</given-names></name><name><surname>Bonaventura</surname><given-names>D</given-names></name><name><surname>Melo</surname><given-names>MC</given-names></name><name><surname>Ambrosio</surname><given-names>SR</given-names></name><name><surname>de Oliveira</surname><given-names>AM</given-names></name><name><surname>Bendhack</surname><given-names>LM</given-names></name><name><surname>da Costa</surname><given-names>FB</given-names></name></person-group><article-title>Pimaradienoic acid inhibits vascular contraction and induces hypotension in normotensive rats</article-title><source>J. Pharm. Pharmacol</source><year>2008</year><volume>60</volume><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1211/jpp.60.4.0007</pub-id><pub-id pub-id-type="pmid">18380917</pub-id></citation></ref>
<ref id="b19-marinedrugs-09-02075"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tirapelli</surname><given-names>CR</given-names></name><name><surname>Ambrosio</surname><given-names>SR</given-names></name><name><surname>de Oliveira</surname><given-names>AM</given-names></name><name><surname>Tostes</surname><given-names>RC</given-names></name></person-group><article-title>Hypotensive action of naturally occurring diterpenes: A therapeutic promise for the treatment of hypertension</article-title><source>Fitoterapia</source><year>2010</year><volume>81</volume><fpage>690</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2010.05.018</pub-id><pub-id pub-id-type="pmid">20685303</pub-id></citation></ref>
<ref id="b20-marinedrugs-09-02075"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somova</surname><given-names>LI</given-names></name><name><surname>Shode</surname><given-names>FO</given-names></name><name><surname>Moodley</surname><given-names>K</given-names></name><name><surname>Govender</surname><given-names>Y</given-names></name></person-group><article-title>Cardiovascular and diuretic activity of kaurene derivates of <italic>Xylopia aethiopica</italic> and <italic>Alepidea amatymbica</italic></article-title><source>J. Ethnopharmacol</source><year>2001</year><volume>77</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(01)00285-9</pub-id><pub-id pub-id-type="pmid">11535360</pub-id></citation></ref>
<ref id="b21-marinedrugs-09-02075"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>AP</given-names></name><name><surname>Furtado</surname><given-names>FF</given-names></name><name><surname>Silva</surname><given-names>MS</given-names></name><name><surname>Tavares</surname><given-names>JF</given-names></name><name><surname>Mafra</surname><given-names>RA</given-names></name><name><surname>Araújo</surname><given-names>DA</given-names></name><name><surname>Cruz</surname><given-names>JS</given-names></name><name><surname>Medeiros</surname><given-names>IA</given-names></name></person-group><article-title>Calcium channel blockade as a target for the cardiovascular effects induced by the 8 (17), 12E, 14 labdatrien-18-oic acid (labdane-302)</article-title><source>Vasc. Pharmacol</source><year>2006</year><volume>44</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2006.01.009</pub-id></citation></ref>
<ref id="b22-marinedrugs-09-02075"><label>22</label><citation citation-type="journal"><collab>American Heart Association</collab><article-title>Heart disease and stroke statistics—2008 update</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>125</fpage><lpage>146</lpage></citation></ref>
<ref id="b23-marinedrugs-09-02075"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefkowits</surname><given-names>RJ</given-names></name><name><surname>Willerson</surname><given-names>J</given-names></name></person-group><article-title>Prospects for cardiovascular research</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>581</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1001/jama.285.5.581</pub-id><pub-id pub-id-type="pmid">11176863</pub-id></citation></ref>
<ref id="b24-marinedrugs-09-02075"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>MRV</given-names></name><name><surname>Moreira</surname><given-names>FV</given-names></name><name><surname>Fraga</surname><given-names>BP</given-names></name><name><surname>de Souza</surname><given-names>DP</given-names></name><name><surname>Bonjardim</surname><given-names>LR</given-names></name><name><surname>Quintans</surname><given-names>LJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Cardiovascular effects of monoterpenes: a review</article-title><source>Rev. Bras. Farmacogn</source><year>2011</year><volume>21</volume><fpage>764</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1590/S0102-695X2011005000119</pub-id></citation></ref>
<ref id="b25-marinedrugs-09-02075"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fluckiger</surname><given-names>JP</given-names></name><name><surname>Sonnay</surname><given-names>M</given-names></name><name><surname>Boillat</surname><given-names>N</given-names></name><name><surname>Atkinson</surname><given-names>J</given-names></name></person-group><article-title>Attenuation of baroreceptor reflex by general anesthetic agent in the normotensive rat</article-title><source>Eur. J. Pharmacol</source><year>1985</year><volume>109</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(85)90545-X</pub-id><pub-id pub-id-type="pmid">3996465</pub-id></citation></ref>
<ref id="b26-marinedrugs-09-02075"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>TL</given-names></name><name><surname>Hutchins</surname><given-names>PM</given-names></name></person-group><article-title>Anesthetic effects on hemodynamics of spontaneously hypertensive on Wistar-Kyoto rats</article-title><source>Am. J. Physiol</source><year>1980</year><volume>238</volume><fpage>539</fpage><lpage>544</lpage></citation></ref>
<ref id="b27-marinedrugs-09-02075"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulvany</surname><given-names>MJ</given-names></name><name><surname>Aalkjaer</surname><given-names>C</given-names></name></person-group><article-title>Structure and function of small arteries</article-title><source>Physiol. Res</source><year>1990</year><volume>70</volume><fpage>921</fpage><lpage>951</lpage></citation></ref>
<ref id="b28-marinedrugs-09-02075"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grover-Páez</surname><given-names>F</given-names></name><name><surname>Zavalza-Gómez</surname><given-names>AB</given-names></name></person-group><article-title>Endothelial dysfunction and cardiovascular risk factors</article-title><source>Diabetes Res. Clin. Pract</source><year>2009</year><volume>84</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2008.12.013</pub-id><pub-id pub-id-type="pmid">19185380</pub-id></citation></ref>
<ref id="b29-marinedrugs-09-02075"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furchgott</surname><given-names>FF</given-names></name><name><surname>Zawadzki</surname><given-names>JV</given-names></name></person-group><article-title>The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine</article-title><source>Nature</source><year>1980</year><volume>288</volume><fpage>373</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/288373a0</pub-id><pub-id pub-id-type="pmid">6253831</pub-id></citation></ref>
<ref id="b30-marinedrugs-09-02075"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Côrtes</surname><given-names>SF</given-names></name><name><surname>Rezende</surname><given-names>BA</given-names></name><name><surname>Corriu</surname><given-names>C</given-names></name><name><surname>Medeiros</surname><given-names>IA</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><name><surname>Lopes</surname><given-names>MJ</given-names></name><name><surname>Lemos</surname><given-names>VS</given-names></name></person-group><article-title>Pharmacological evidence for the activation of potassium channels as the mechanism involved in the hypotensive and vasorelaxant effect of dioclein in rat small resistance arteries</article-title><source>Br. J. Pharmacol</source><year>2001</year><volume>133</volume><fpage>849</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704147</pub-id><pub-id pub-id-type="pmid">11454658</pub-id></citation></ref>
<ref id="b31-marinedrugs-09-02075"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McNeill</surname><given-names>JR</given-names></name><name><surname>Jurgens</surname><given-names>TM</given-names></name></person-group><article-title>A systematic review of mechanisms by which natural products of plant origin evoke vasodilation</article-title><source>Can. J. Phys. Pharmacol</source><year>2006</year><volume>84</volume><fpage>803</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1139/Y06-028</pub-id></citation></ref>
<ref id="b32-marinedrugs-09-02075"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Oh</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Cho</surname><given-names>KW</given-names></name><name><surname>Kanga</surname><given-names>DG</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name></person-group><article-title>Ethanol extract of seeds of <italic>Oenothera odorata</italic> induces vasorelaxation via endothelium dependent NO-cGMP signaling through activation of Akt-eNOS-sGC pathway</article-title><source>J. Ethnopharmacol</source><year>2011</year><volume>133</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.09.024</pub-id><pub-id pub-id-type="pmid">20932888</pub-id></citation></ref>
<ref id="b33-marinedrugs-09-02075"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>TP</given-names></name><name><surname>Porto</surname><given-names>DL</given-names></name><name><surname>Menezes</surname><given-names>CP</given-names></name><name><surname>Antunes</surname><given-names>AA</given-names></name><name><surname>Silva</surname><given-names>DF</given-names></name><name><surname>Sousa</surname><given-names>DP</given-names></name><name><surname>Nakao</surname><given-names>LS</given-names></name><name><surname>Braga</surname><given-names>VA</given-names></name><name><surname>Medeiros</surname><given-names>IA</given-names></name></person-group><article-title>Unravelling the cardiovascular effects induced by α-terpineol: A role for the nitric oxide–cGMP pathway</article-title><source>Clin. Exp. Pharmacol. Phys</source><year>2010</year><volume>37</volume><fpage>811</fpage><lpage>816</lpage></citation></ref>
<ref id="b34-marinedrugs-09-02075"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somlyo</surname><given-names>AP</given-names></name><name><surname>Somlyo</surname><given-names>AV</given-names></name></person-group><article-title>Signal transduction and regulation in smooth muscle</article-title><source>Nature</source><year>1994</year><volume>372</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/372231a0</pub-id><pub-id pub-id-type="pmid">7969467</pub-id></citation></ref>
<ref id="b35-marinedrugs-09-02075"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ratz</surname><given-names>PH</given-names></name><name><surname>Berg</surname><given-names>KM</given-names></name></person-group><article-title>2-Aminoethoxydiphenyl borate inhibits KCl-induced vascular smooth muscle contraction</article-title><source>Eur. J. Pharmacol</source><year>2006</year><volume>541</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2006.05.014</pub-id><pub-id pub-id-type="pmid">16765942</pub-id></citation></ref>
<ref id="b36-marinedrugs-09-02075"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro-Gonzalez</surname><given-names>MF</given-names></name><name><surname>Grayson</surname><given-names>TH</given-names></name><name><surname>Meaney</surname><given-names>KR</given-names></name><name><surname>Cribbs</surname><given-names>LL</given-names></name><name><surname>Hill</surname><given-names>CE</given-names></name></person-group><article-title>Non-L-type voltage-dependent calcium channels control vascular tone of the rat basilar artery</article-title><source>Clin. Exp. Pharmacol. Phys</source><year>2009</year><volume>36</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2008.05035.x</pub-id></citation></ref>
<ref id="b37-marinedrugs-09-02075"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braga</surname><given-names>VA</given-names></name></person-group><article-title>Dietary salt enhances angiotensin-II-induced superoxide formation in the rostral ventrolateral medulla</article-title><source>Auton Neurosci Basic Clin</source><year>2010</year><volume>155</volume><fpage>14</fpage><lpage>18</lpage><comment><italic>Samples Availability:</italic> Available from the authors.</comment><pub-id pub-id-type="doi">10.1016/j.autneu.2009.12.007</pub-id></citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-marinedrugs-09-02075" position="float">
<label>Figure 1</label>
<caption>
<p>(<bold>A</bold>) Representative original tracings showing the changes in pulse arterial pressure (PAP, mmHg), mean arterial pressure (MAP, mmHg), and heart rate (HR, b.p.m.); (<bold>B</bold>) Changes in mean arterial pressure (MAP) and heart rate (HR) induced by the acute administration of increasing doses of CME (mg/kg, i.v) and vehicle. Values are expressed by mean ± SEM. (<italic>n</italic> = 5).</p></caption>
<graphic xlink:href="marinedrugs-09-02075f1.gif"/></fig>
<fig id="f2-marinedrugs-09-02075" position="float">
<label>Figure 2</label>
<caption>
<p>Concentration–response curves showing the relaxant effect of (<bold>A</bold>) CME (0.01–500 μg/mL); and (<bold>B</bold>) Hexane/EtOAc Phase (HEP) (0.01–500 μg/mL) on Phe (1 μM)-pre-contracted mesenteric artery rings with (■, <italic>n</italic> = 7) and without (□, <italic>n</italic> = 7) vascular endothelium, respectively. Values are expressed by mean ± SEM.</p></caption>
<graphic xlink:href="marinedrugs-09-02075f2.gif"/></fig>
<fig id="f3-marinedrugs-09-02075" position="float">
<label>Figure 3</label>
<caption>
<p>Concentration–response curves showing the relaxant effect elicited by CME (0.01–500 μg/mL, <italic>n</italic> = 6) in the presence of (<bold>A</bold>) KCl (20 mM) (♦) or TEA 3 mM (○); (<bold>B</bold>) KCl (60 mM) (●) or U-46619; (□) represents phenyephrine pre-contracted mesenteric rings without endothelium; (<bold>C</bold>) Vasorelaxant effect elicited by HEP (0.01–500 μg/mL) on KCl 60 mM-pre-contracted mesenteric artery rings (●) and Phe (1 μM)-pre-contracted mesenteric rings without endothelium (<italic>n</italic> = 7). Values are expressed by mean ± SEM.</p></caption>
<graphic xlink:href="marinedrugs-09-02075f3a.gif"/>
<graphic xlink:href="marinedrugs-09-02075f3b.gif"/></fig>
<fig id="f4-marinedrugs-09-02075" position="float">
<label>Figure 4</label>
<caption>
<p>Effects of (<bold>A</bold>) CME and (<bold>B</bold>) HEP on CaCl<sub>2</sub>-induced contraction in endothelium-denuded mesenteric artery rings. Concentration-response curves for CaCl<sub>2</sub> were determined in Ca<sup>2+</sup>-free solution containing KCl (60 mM). The curves were determined in the absence (control, ■) and after incubation with CME in (<bold>A</bold>) or HEP in (<bold>B</bold>) (▾) 0.03; (●) 0.3; (▵) 10; (⋄) 30; (×) 100 μg/mL, <italic>n</italic> = 7. * Significantly different from control (<italic>p</italic> &lt; 0.05).</p></caption>
<graphic xlink:href="marinedrugs-09-02075f4.gif"/></fig>
<fig id="f5-marinedrugs-09-02075" position="float">
<label>Figure 5</label>
<caption>
<p>Effect of increasing concentrations of CME (0.01–500 μg/mL, <italic>n</italic> = 7) on phenylephrine (Phe, 1 μM) (□) or KCl (20 mM) plus S(−)-BayK 8644 (10<sup>−7</sup> M) (▴) induced contractions in isolated mesenteric artery rings without endothelium. Values are expressed by mean ± SEM.</p></caption>
<graphic xlink:href="marinedrugs-09-02075f5.gif"/></fig>
<fig id="f6-marinedrugs-09-02075" position="float">
<label>Figure 6</label>
<caption>
<p>Concentration–response curves showing the relaxant effect elicited by (<bold>A</bold>) CME (0.01–500 μg/mL); and (<bold>B</bold>) HEP (0.01–500 μg/mL) in the presence of nifedipine (×, <italic>n</italic> = 6); (□) represents phenyephrine pre-contracted mesenteric rings without endothelium. Values are expressed by mean ± SEM. * Significantly different from control (<italic>p</italic> &lt; 0.05).</p></caption>
<graphic xlink:href="marinedrugs-09-02075f6.gif"/></fig></sec></back></article>
